menu
    • menu
    [{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Telomir Pharmaceuticals

    Menu

    Telomir Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Telomir Pharmaceuticals

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Telomir Pharmaceuticals

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telomir-1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Telomir Pharma Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

                            Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

                            Brand Name : Telomir-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : Telomir-1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Telomir Pharmaceuticals

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Telomir Pharmaceuticals

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telomir-1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Telomir’s Dr. Michael Roizen to Present Preclinical Data for Telomir-1 in 2024

                            Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

                            Brand Name : Telomir-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 02, 2024

                            Lead Product(s) : Telomir-1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth